Trial Profile
A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Bintrafusp alfa (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- 27 Oct 2022 Status changed from completed to discontinued.
- 26 Oct 2022 Status changed from recruiting to completed.
- 22 Sep 2022 Planned End Date changed from 31 Oct 2021 to 31 Oct 2022.